Ed Arce Analyst Performance

Senior Research Analyst, Biotechnology at Westpark Capital

Ed Arce is a stock analyst at Westpark Capital in the healthcare sector, covering 25 publicly traded companies. Over the past year, Ed Arce has issued 3 stock ratings, including and buy recommendations. While full access to Ed Arce's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Ed Arce's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
69 Last 11 Years
Buy Recommendations
94.20% 65 Buy Ratings
Companies Covered
25 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy94.2%65 ratings
Hold5.8%4 ratings
Sell0.0%0 ratings

Out of 69 total stock ratings issued by Ed Arce at Westpark Capital, the majority (94.2%) have been Buy recommendations, followed by 5.8% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.0% of companies on NASDAQ
24 companies
OTCMKTS
4.0% of companies on OTCMKTS
1 company

Ed Arce, an analyst at Westpark Capital, currently covers 25 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
25 companies
100.0%

Ed Arce of Westpark Capital specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
17 companies
68.0%
PHARMACEUTICALS
8 companies
32.0%

About Ed Arce

Ed Arce joined WestPark Capital as a Managing Director to build a leading healthcare research platform. Mr. Arce covers emerging and small-to-midcap (SMID) biotechnology companies, focused on several therapeutic areas including hepatology; cardiovascular, renal & metabolism (CRM); inflammation & immunology (I&I); gastroenterology; and rare diseases. Mr. Arce brings nearly 20 years of experience with prior appointments at H.C. Wainwright, Roth Capital Partners, MLV & Co., Wedbush Securities and UBS Securities. In 2017, Mr. Arce was awarded the No. 1 Stock Picker in Biotechnology in the United States by the Thomson Reuters Analyst Awards. Mr. Arce holds a B.S. in Civil Engineering and an MBA from Florida International University, an M.S. in Finance from Boston College, and an Executive Education Certificate by completing the Chief Financial Officer (CFO) Program from Columbia University. Mr. Arce holds the Series 7, 63, 86, and 87 registrations.

Ed Arce's Ratings History at Westpark Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Veru Inc. stock logo
VERU
Veru
10/6/2026Initiated Coverage$2.60Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
9/8/2026Initiated Coverage$0.98$4.50Buy
Talphera, Inc. stock logo
TLPH
Talphera
4/30/2026Initiated Coverage$0.90$3.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
9/30/2025Boost Price Target$15.16$28.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
9/2/2025Initiated Coverage$8.40$24.00Buy
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
6/11/2025Upgrade$15.13$30.00Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
4/11/2025Reiterated Rating$5.30$75.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
4/10/2025Reiterated Rating$8.86$60.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4/4/2025Reiterated Rating$1.88$7.50Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
4/1/2025Boost Price Target$5.75$75.00Buy
Talphera, Inc. stock logo
TLPH
Talphera
4/1/2025Reiterated Rating$0.50$6.00Buy
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3/31/2025Reiterated Rating$9.12$70.00Buy
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
3/28/2025Reiterated Rating$2.94$13.00Buy
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3/24/2025Reiterated Rating$11.01Neutral
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3/19/2025Reiterated Rating$8.36$240.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3/14/2025Reiterated Rating$1.69$7.50Buy
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3/11/2025Lower Price Target$10.41$70.00Buy
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3/11/2025Reiterated Rating$3.33$32.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3/10/2025Boost Price Target$23.66$35.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3/7/2025Lower Price Target$14.31$60.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3/3/2025Boost Price Target$49.12$75.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2/28/2025Boost Price Target$46.97$72.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2/27/2025Boost Price Target$355.88$405.00Buy
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2/14/2025Reiterated Rating$43.52$95.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2/14/2025Reiterated Rating$17.79$63.00Buy
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2/11/2025Reiterated Rating$4.90$18.00Buy
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2/10/2025Downgrade$7.79Neutral
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2/7/2025Reiterated Rating$3.99$13.00Buy
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
1/30/2025Reiterated Rating$2.53$13.00Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
1/29/2025Reiterated Rating$5.39$40.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
1/27/2025Boost Price Target$51.68$72.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1/23/2025Reiterated Rating$2.32$7.50Buy
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
1/21/2025Reiterated Rating$3.20$5.00Buy
Talphera, Inc. stock logo
TLPH
Talphera
1/21/2025Reiterated Rating$0.67$6.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
1/16/2025Reiterated Rating$22.45$50.00Buy
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
1/15/2025Boost Price Target$17.07$22.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
1/14/2025Boost Price Target$303.70$400.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1/14/2025Reiterated Rating$1.88$7.50Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
1/13/2025Reiterated Rating$16.63$63.00Buy
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
1/10/2025Reiterated Rating$15.54$240.00Buy
CFA: Bank of America Said THIS (Ad)

On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel

Click here to watch how to become your own bank before the switch flips.